Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
18 hedge funds and large institutions have $36.2M invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.73% more ownership
Funds ownership: 0% → 2.73% (+2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
Governors Lane
New York
|
+$7.63M |
| 2 |
6CM
683 Capital Management
New York
|
+$7.39M |
| 3 |
SRCM
Sage Rock Capital Management
New York
|
+$3.44M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.17M |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
+$2.85M |
Top Sellers
CERE Hedge Fund Activity: Q3 2020 in Review
18 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q3 2020, worth a combined $36.2M.
Buyers outnumbered sellers: 18 funds opened new CERE positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Governors Lane, opening a new position worth an estimated $7.63M.
- 18 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $36.2M of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q3 2020.
- 18 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +18 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q3 2020 was Governors Lane, an estimated $7.63M added.
Based on aggregated 13F filings for Q3 2020.